Abstract: A capacitance detection apparatus and an electronic device are disclosed. The capacitance detection apparatus includes: a sensing module, a connecting circuit, and a differential detection circuit for detecting changes in capacitance of the sensing module; the sensing module comprises: a substrate, and a first sensing layer and a second sensing layer respectively located on two sides of the substrate; a first sensing unit of the first sensing layer is opposite to a second sensing unit of the second sensing layer, and the first sensing unit covers the second sensing unit; the first sensing unit and the second sensing unit are electrically connected to the differential detection circuit. When a detection object approaches the capacitance detection apparatus, the capacitance of the first sensing unit is influenced by the temperature and the detection object, and the capacitance of the second sensing unit is only influenced by the temperature.

Abstract: Systems and methods in accordance with various embodiments of the invention perform lossless source coding. Nested code structures are utilized to perform Random Access Source Coding (RASC), where the number of active encoders is initially unknown. Decoders can attempt to source decode using a number of Slepian-Wolf decoders corresponding to an estimated number of sources. Multiple source encoders are configured to receive start messages and transmit portions of codewords, selected by source encoding data from sources to remove redundancy, until an end of epoch message is received.

Abstract: Systems and methods in accordance with various embodiments of the invention perform lossless source coding. In several embodiments, a nested code structure is utilized to perform Random Access Source Coding (RASC), where the number of active encoders is initially unknown. In several embodiments, the decoder can attempt to decode using a number of Slepian-Wolf decoders corresponding to an estimated number of sources. One embodiment includes multiple source encoders configured to receive a start message and transmit a portion of a codeword selected by encoding data from a source until an end of epoch message is received. A source decoder can transmit at least one start message, and receive codeword portions transmitted by the plurality of source encoders. When a decoding rule is satisfied, the source decoder can decode data from multiple source encoders based upon received codeword portions, and cause the broadcast transmitter to transmit an end of epoch message.

Abstract: Disclosed are an rTRAIL mutant and monomethyl auristatin E (MMAE) conjugate thereof. The amino acid sequence thereof is as represented by SEQ ID No.1. Also disclosed are a coding gene of the rTRAIL mutant and expression system, recombinant vector and expression unit containing the coding gene. Also disclosed are an rTRAIL mutant-vcMMAE conjugate and preparation and uses thereof. The conjugate of the present invention has the biological functions of both the rTRAIL mutant and the MMAE; the MMAE is directionally transferred to a tumor cell through the specific binding between the rTRAIL mutant and a death receptor on the surface of the tumor cell, and is released and takes effect in the tumor cell, thus killing the tumor cells less sensitive or even resistant to TRAIL, and reducing the toxicity generated by the separate administration of the MMAE.

Abstract: Disclosed are an rTRAIL mutant and monomethyl auristatin E (MMAE) conjugate thereof. The amino acid sequence thereof is as represented by SEQ ID No.1. Also disclosed are a coding gene of the rTRAIL mutant and expression system, recombinant vector and expression unit containing the coding gene. Also disclosed are an rTRAIL mutant-vcMMAE conjugate and preparation and uses thereof. The conjugate of the present invention has the biological functions of both the rTRAIL mutant and the MMAE; the MMAE is directionally transferred to a tumor cell through the specific binding between the rTRAIL mutant and a death receptor on the surface of the tumor cell, and is released and takes effect in the tumor cell, thus killing the tumor cells less sensitive or even resistant to TRAIL, and reducing the toxicity generated by the separate administration of the MMAE.